Elzbieta Zlowocka-Perlowska | Micronutrients and Kidney Cancer | Best Researcher Award

Published on by Cognitive Scientist Awards

Dr. Elzbieta Zlowocka-Perlowska | Micronutrients and Kidney Cancer | Best Researcher Award

Pomeranian Medical University | Poland

Dr. Elżbieta Złowocka-Perłowska is an accomplished Polish medical scientist specializing in molecular oncology and hereditary cancer research. She earned her master’s degree in biology from the University of Szczecin and a doctorate in medical sciences with highest distinction from the Pomeranian Medical University in Szczecin, where she currently serves at the Center for Hereditary Tumors and the Department of Genetics and Pathomorphology. Her professional expertise lies in molecular diagnostics, cancer biomarkers, and the prognostic role of trace and microelements in bladder and kidney cancers. She leads innovative research investigating correlations between blood and serum element levels and patient survival, aiming to integrate these biomarkers into predictive cancer models for personalized therapy development. Dr. Złowocka-Perłowska possesses strong research skills in molecular genetics, laboratory diagnostics, epidemiological modeling, and translational oncology. Her distinguished career includes numerous national and international awards, such as recognition from the World Scientist Forum and multiple Rector’s Awards, along with significant contributions to over fifty scientific publications and several patents. She has also collaborated internationally and mentored emerging researchers. Through her pioneering work, Dr. Złowocka-Perłowska continues to advance the understanding of hereditary and molecular mechanisms in cancer, contributing to future innovations in clinical diagnostics and targeted therapies.

Profile: ORCID

Featured Publications

Sahar Mohammadnabizadeh | Health Education | Best Researcher Award

Published on by Cognitive Scientist Awards

Dr. Sahar Mohammadnabizadeh | Health Education | Best Researcher Award

Mashhad University of Medical Sciences | Iran

Dr. Sahar Mohammadnabizadeh is an accomplished Iranian health educationalist and environmental scientist with extensive expertise in health promotion, public health, environmental health, and social determinants of health. She earned her Ph.D. in Health Education and Health Promotion from Kurdistan University of Medical Sciences, where her research focused on evaluating the effects of educational interventions on vitamin consumption behavior among factory workers using Protection Motivation Theory. She also holds a master’s degree in Environmental Pollution from the University of Birjand, where she investigated heavy metal bioaccumulation in fish, and a bachelor’s degree in Environmental Science from Ferdowsi University of Mashhad. Professionally, she serves as a researcher at the Social Determinants of Health Research Centre and an environmental consultant, while teaching courses on health, safety, and environmental protection at multiple universities. Her research interests encompass health behavior theories, preventive health interventions, social and behavioral sciences, environmental pollutants, and community health promotion, supported by strong skills in research methodology, data collection, statistical analysis using SPSS, STATA, AMOS, Python, and GIS, alongside project management and scientific writing. She has received multiple recognitions for her contributions to research and education, including participation in international congresses, awards for student research, and editorial responsibilities. Her career reflects a consistent commitment to advancing health literacy, promoting well-being, and applying interdisciplinary approaches to solve public health and environmental challenges, demonstrating both scholarly excellence and societal impact.

Profile: Google scholar

Featured Publications

Seyed-Mahmood Seyed-Khorrami | Cancer | Best Researcher Award

Published on by Cognitive Scientist Awards

Assist. Prof. Dr. Seyed-Mahmood Seyed-Khorrami | Cancer | Best Researcher Award

Tarbiat Modares University | Iran

Seyed-Mahmood Seyed-Khorrami is a medical virologist with advanced academic training, holding a doctorate in medical virology from Tarbiat Modares University, a master’s degree in medical virology from Tehran University of Medical Sciences, and a bachelor’s degree in biology from Tabriz University. His professional experience spans diverse roles, including specialty expert at the Center for Disease Control and Prevention, laboratory technical officer and manager in research and development, consultant virologist in an HPV clinic, and active member of national COVID-19 diagnostic and research projects. He has also contributed as a teaching assistant in cell culture, virus propagation, and molecular techniques. His research interests focus on oncolytic viruses in cancer therapy, viral pathogenesis, emerging and re-emerging viral diseases, animal experiments, and nanotechnology-based vaccines and delivery systems. He possesses strong laboratory expertise in virus propagation, molecular diagnostics, cloning, flow cytometry, animal handling, and bioinformatics, alongside certifications in biosafety, GLP, and quality management. His publication record includes impactful contributions in international journals on cancer immunotherapy, COVID-19, viral epidemiology, and nanovaccine development, complemented by book authorship and conference presentations. He has served as a reviewer for multiple journals and has secured competitive grants for his research. Recognized for his scientific contributions, he demonstrates an outstanding blend of research skills, professional commitment, and leadership. In conclusion, his career reflects a dynamic integration of virology, translational research, and innovation with promising potential for impactful contributions to global health.

Profile: Google scholar

Featured Publications

Tanyanika Phillips | Care Delivery in Thoracic Oncology | Best Researcher Award

Published on by Cognitive Scientist Awards

Dr. Tanyanika Phillips | Care Delivery in Thoracic Oncology | Best Researcher Award

City of Hope National Med Center | United States

Dr. Tanyanika Phillips is an accomplished physician and academic leader specializing in thoracic and geriatric oncology. Currently serving as Assistant Professor in the Department of Medical Oncology and Therapeutics Research at City of Hope National Medical Center, she integrates patient care, research, and community health advocacy. Her professional journey reflects a steadfast dedication to improving cancer care across diverse populations, with a special focus on equity in access and outcomes. Throughout her career, she has held pivotal roles as a clinician, researcher, and administrator, contributing to health system development, rural oncology programs, and national initiatives in cancer equity. Known for her commitment to advancing inclusive research, Dr. Phillips has been instrumental in developing geriatric oncology services and clinical trials that address the needs of aging populations. Her career is distinguished by numerous leadership positions, prestigious awards, and recognition for her community-focused work in eliminating health disparities.

Profile

Scopus

Education

Dr. Tanyanika Phillips’ educational foundation reflects a balance of clinical excellence and population health. She earned her Bachelor of Science in Biology from Xavier University of Louisiana, followed by her Doctor of Medicine from the University of Rochester School of Medicine and Dentistry. Her interest in public health and health outcomes led her to pursue a Master of Public Health at Vanderbilt University, specializing in population-based studies and non-experimental design. She furthered her training through an internal medicine residency at Ochsner Clinic Foundation, a geriatric fellowship at Vanderbilt, and a prestigious medical oncology fellowship at the Sidney Kimmel Cancer Center at Johns Hopkins University. She also completed K12 Research training at Vanderbilt, emphasizing outcomes-based cancer research. Her executive education at Harvard School of Public Health and Case Western Reserve University enhanced her expertise in leadership, project management, and measurement design. This multidisciplinary academic preparation laid the groundwork for her career in oncology research, clinical innovation, and health equity.

Experience

Dr. Tanyanika Phillips has built a dynamic career across academic medicine, community oncology, and health equity leadership. She began as Assistant Professor at Case Western University, where she also directed the Health Equity Initiative in Cancer. Her dedication to accessible oncology care expanded during her tenure as a staff physician at St. John Medical Center and CHRISTUS Health, where she also served as Medical Director for Rural and Community Health. At Antelope Valley Hospital, she led the cancer program as Medical Director before joining City of Hope, where she has since shaped geriatric oncology programs, served as Site Research Champion, and directed community-focused cancer initiatives. In her current role, she balances clinical care and research, directing City of Hope’s Antelope Valley Cancer Program while advancing clinical trials in aging and thoracic oncology. Her leadership positions include Deputy Director of the Center for Cancer and Aging and Enterprise Champion for Advancing Inclusive Research.

Awards and Honors

Dr. Tanyanika Phillips’ career is marked by consistent recognition for excellence in medicine, leadership, and community service. Early in her journey, she received the Community of Caring Award from Ochsner Medical Foundation and the Futures Scholar distinction from the American Medical Directors Association. Her research potential was recognized with the American Society of Clinical Oncology Young Investigator Award. She has also been honored with a Certificate of Special Congressional Recognition for her leadership in Ohio. Her dedication to minority health and community empowerment was acknowledged through multiple awards, including the Unsung Hero Award from the North Coast Nurses Coalition and the Minority Faculty Development Award at University Hospitals Case Medical Center. At St. John Medical Center, she received Values in Action Awards for Human Dignity, Wisdom, and Presence. More recently, her contributions at City of Hope earned her the Values in Action Award for Collaboration and the 2025 Hope Colleague Award.

Research Focus

Dr. Tanyanika Phillips’ research interests are centered on thoracic oncology, geriatric oncology, and advancing equity in cancer care. She is particularly committed to designing and implementing clinical trials that address the unique needs of aging patients with cancer. Her work integrates population-based research methods, health outcomes assessment, and translational oncology to bridge gaps between laboratory advances and real-world applications. As a site research champion and program lead for geriatric oncology at City of Hope, she has facilitated community-based clinical trials aimed at improving access and participation among underrepresented populations. She is also deeply engaged in health equity research, focusing on reducing disparities in cancer outcomes through inclusive trial design and community navigation programs. Her leadership in advancing inclusive research has established her as a key figure in initiatives that integrate cancer biology, geriatrics, and population health, ensuring that scientific discoveries translate into equitable patient care.

 

Publications

 

Title: Clin-STAR Corner: Practice Changing Advances at the Interface of Oncology and Geriatrics
Year: 2025

Title: Smoking prevalence and association with sociodemographic variables in cancer clinical trial participants
Year: 2025

Conclusion

Dr. Tanyanika Phillips stands as a distinguished oncologist, educator, and leader whose career reflects an enduring commitment to patient-centered care, health equity, and translational research, integrating clinical excellence with a vision for advancing inclusive and community-driven oncology practice.

Natalia Baran | Cancer Research | Best Researcher Award

Published on by Cognitive Scientist Awards

Assist. Prof. Dr. Natalia Baran | Cancer Research | Best Researcher Award

Leading Attending at InselSpital Bern, Switzerland.

Dr. Natalia Baran is an Assistant Professor in the Department of Leukemia at MD Anderson Cancer Center, where she focuses on developing novel therapeutic strategies targeting metabolic vulnerabilities in leukemia. Her expertise lies in understanding how metabolic reprogramming can lead to drug resistance and contribute to leukemia progression. With a medical background and extensive experience in both clinical and research settings, Dr. Baran has been at the forefront of studies that aim to modulate metabolic pathways to enhance anti-leukemic responses. By combining insights from molecular biology, immunology, and clinical practice, she is actively working toward discovering innovative treatments for leukemia. Dr. Baran’s research holds great promise in advancing leukemia therapy, particularly by targeting metabolic reprogramming in the context of therapy resistance. Her multidisciplinary approach, integrating clinical data with laboratory research, makes her a key figure in leukemia research.

Profile

Scopus

Google Scholar

Orcid

Education:

Dr. Natalia Baran completed her undergraduate studies in Biotechnology, earning a Master of Science degree in 2006 from Wroclaw University of Science and Technology in Poland. She further pursued medical education and obtained her Medical Doctor (MD) degree from Wroclaw Medical University in 2007. Driven by her passion for research, Dr. Baran earned a Ph.D. in Medicine from the University of Bonn in 2015. Her doctoral research laid the foundation for her current focus on leukemia and metabolic reprogramming. In addition, Dr. Baran underwent extensive postdoctoral training at MD Anderson Cancer Center, where she honed her expertise in hematology and oncology, contributing significantly to translational research in leukemia. Her diverse educational background, blending science and medicine, has shaped her comprehensive approach to cancer research.

Professional Experience:

Dr. Baran has a rich professional experience that bridges clinical practice and cutting-edge research. After completing her MD, she pursued clinical residencies in Internal Medicine, Hematology, and Oncology at prestigious German institutions, including the University of Heidelberg and the University of Bonn. This clinical experience laid the groundwork for her subsequent focus on leukemia research. In 2016, she joined MD Anderson Cancer Center as a Postdoctoral Fellow in the Department of Leukemia. During her postdoctoral tenure, Dr. Baran worked closely with Dr. Marina Konopleva, exploring the role of metabolic pathways in leukemia resistance. By 2022, she had transitioned to an Assistant Professor role, continuing her translational research in leukemia, with a particular emphasis on identifying novel therapeutic strategies. Her clinical and research experiences synergize to enhance her contributions to the leukemia research community.

Research Interests:

Dr. Baran’s research is primarily centered on exploring metabolic vulnerabilities and their role in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Her work seeks to understand the mechanisms through which metabolic reprogramming in leukemia cells contributes to drug resistance and tumor progression. Dr. Baran is particularly interested in how modulating the metabolic environment can enhance the effectiveness of leukemia therapies. By focusing on the interplay between metabolism and leukemic cell survival, she aims to identify new therapeutic strategies that target metabolic pathways to overcome resistance to traditional treatments. Her research also explores how immune modulation can be integrated with metabolic interventions to develop more efficient leukemia therapies.

Awards and Honors:

Dr. Baran has received recognition for her contributions to leukemia research, although specific awards are not detailed in available sources. However, her research has been featured prominently in major scientific forums, including the Annual Metabolism in Cancer Symposium organized by MD Anderson. Her work has earned her respect within the scientific community, as evidenced by her continued role as an Assistant Professor and her involvement in prestigious cancer research initiatives. Dr. Baran’s impact is evident in her ongoing efforts to bridge the gap between basic science and clinical application, aiming to revolutionize leukemia treatment.

Skills:

Dr. Baran’s research skills encompass a wide range of techniques in molecular biology, cell culture, and metabolic analysis. She is highly proficient in studying the metabolic pathways that drive leukemia, using state-of-the-art technologies such as high-resolution metabolic flux analysis, RNA sequencing, and advanced cell imaging. Dr. Baran is skilled at integrating basic science with clinical data, ensuring that her research translates into practical therapeutic interventions. Her expertise in immunology further complements her research in leukemia, allowing her to investigate the potential of combining metabolic therapies with immune modulation to improve patient outcomes. Her interdisciplinary approach is a key strength in her ongoing work in leukemia research.

Publication Top Notes

A Selective BCL-XL PROTAC Degrader Achieves Safe and Potent Antitumor Activity

  • Authors: S Khan, X Zhang, D Lv, Q Zhang, Y He, P Zhang, X Liu, D Thummuri, et al.
  • Journal: Nature Medicine
  • Volume: 25(12), Pages 1938–1947
  • Cited by: 515
  • Year: 2019

Targeting a Cytokine Checkpoint Enhances the Fitness of Armored Cord Blood CAR-NK Cells

  • Authors: M Daher, R Basar, E Gokdemir, N Baran, N Uprety, AK Nunez Cortes, et al.
  • Journal: Blood, The Journal of the American Society of Hematology
  • Volume: 137(5), Pages 624–636
  • Cited by: 226
  • Year: 2021

Inhibiting Glutaminase in Acute Myeloid Leukemia: Metabolic Dependency of Selected AML Subtypes

  • Authors: P Matre, J Velez, R Jacamo, Y Qi, X Su, T Cai, SM Chan, A Lodi, et al.
  • Journal: Oncotarget
  • Volume: 7(48), Pages 79722
  • Cited by: 194
  • Year: 2016

Complex I Inhibitor of Oxidative Phosphorylation in Advanced Solid Tumors and Acute Myeloid Leukemia: Phase I Trials

  • Authors: TA Yap, N Daver, M Mahendra, J Zhang, C Kamiya-Matsuoka, et al.
  • Journal: Nature Medicine
  • Volume: 29(1), Pages 115–126
  • Cited by: 182
  • Year: 2023

Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy

  • Authors: N Baran, M Konopleva
  • Journal: Clinical Cancer Research
  • Volume: 23(10), Pages 2382–2390
  • Cited by: 126
  • Year: 2017

Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-Like Responses Against CD30+ Malignancies

  • Authors: LN Kerbauy, ND Marin, M Kaplan, PP Banerjee, MM Berrien-Elliott, et al.
  • Journal: Clinical Cancer Research
  • Volume: 27(13), Pages 3744–3756
  • Cited by: 117
  • Year: 2021

Clonal Selection and Therapy Resistance in Acute Leukemias: Mathematical Modelling Explains Different Proliferation Patterns at Diagnosis and Relapse

  • Authors: T Stiehl, N Baran, AD Ho, A Marciniak-Czochra
  • Journal: Journal of The Royal Society Interface
  • Volume: 11(94), Article ID 20140079
  • Cited by: 106
  • Year: 2014

Activation of RAS/MAPK Pathway Confers MCL-1 Mediated Acquired Resistance to BCL-2 Inhibitor Venetoclax in Acute Myeloid Leukemia

  • Authors: Q Zhang, B Riley-Gillis, L Han, Y Jia, A Lodi, H Zhang, S Ganesan, R Pan, et al.
  • Journal: Signal Transduction and Targeted Therapy
  • Volume: 7(1), Article ID 51
  • Cited by: 104
  • Year: 2022

Conclusion:

Dr. Natalia Baran is a prominent researcher whose work in leukemia has the potential to transform therapeutic approaches, especially through targeting metabolic pathways. Her strong academic background, combined with extensive clinical and research experience, enables her to address one of the most pressing challenges in leukemia treatment: drug resistance. By focusing on metabolic reprogramming, Dr. Baran is paving the way for innovative strategies to combat leukemia and improve patient outcomes. Her expertise in integrating basic research with clinical applications ensures that her contributions will have a lasting impact on the field of oncology, particularly in the development of new, more effective therapies for leukemia.